[Skip to Content]

Claim CME

Women's Health

Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast CancerA Review

Educational Objective
To identify the key insights or developments described in this article

1 Credit CME

JAMA Oncology

Published Online: January 13, 2022

Review

Article Information and Disclosures

Paolo Tarantino, MD^1,2,3;

Giuseppe Curigliano, MD, PhD^1,2;

Heather A. Parsons, MD, MPH^3,4;

et al

Nancy U. Lin, MD^3,4;

Ian Krop, MD, PhD^3,4;

Elizabeth A. Mittendorf, MD, PhD^3,4,5;

Adrienne Waks, MD^3,4;

Eric P. Winer, MD^3,4;

Sara M. Tolaney, MD, MPH^3,4

Author Affiliations

¹Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy
²Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
³Dana-Farber Cancer Institute, Boston, Massachusetts
⁴Harvard Medical School, Boston, Massachusetts
⁵Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, Massachusetts

Read article on JAMA Network

Read Article Claim CME

Abstract

Importance Metastatic breast cancer (MBC) has traditionally been considered incurable. Accordingly, current treatment algorithms are aimed at maintaining quality of life and improving overall survival, rather than at complete eradication of the disease. Attempts to achieve cure with high-dose chemotherapy were conducted in the 1990s, with no observed long-term benefit compared with conventional chemotherapy. Nonetheless, Erb-B2 receptor tyrosine kinase 2 (ERBB2, formerly HER2)-targeted biologic treatments, developed in the past 2 decades, are currently challenging this paradigm. Indeed, a fraction of patients with ERBB2-positive MBC achieve long-lasting responses to chemotherapy and ERBB2-blockade, resembling a cure. In this setting, the challenge of identifying the optimal curable population has emerged, including identifying populations in whom treatment escalation strategies may be beneficial, while avoiding overtreatment in patients with incurable disease.

Observations A number of clinical and pathologic features allow physicians to identify patients with ERBB2-positive MBC who are more likely to experience a long-lasting response to chemotherapy and ERBB2-blockade. Long-term responders tend to be de novo metastatic, have a reduced disease burden, and tend to show deep responses to systemic treatment. In pathologic terms, features associated with long-term response are high ERBB2 expression, lack of detrimental genomic aberrations, and antitumor immune activation. This population of patients may potentially derive benefit from a tailored escalation of frontline treatment with novel anti-ERBB2 drugs, such as trastuzumab deruxtecan, tucatinib, or margetuximab. Additional recent therapeutic and diagnostic advancements could further aid in the path toward a cure for ERBB2-positive MBC.

Conclusions and Relevance Careful implementation of novel diagnostic and treatment tools could potentially expand the population of patients with ERBB2-positive MBC experiencing long-lasting disease response. Trials are in preparation to confirm this paradigm, and hopefully lead to a new era of precision therapy for breast cancer.

Claim CME

Buy This Activity

Article Information

Accepted for Publication: October 5, 2021.

Published Online: January 13, 2022. doi:10.1001/jamaoncol.2021.6597

Corresponding Author: Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215 (sara_tolaney@dfci.harvard.edu).

Author Contributions: Dr Tarantino had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Tarantino, Curigliano, Parsons, Krop, Winer, Tolaney.

Acquisition, analysis, or interpretation of data: Tarantino, Curigliano, Lin, Mittendorf, Waks, Tolaney.

Drafting of the manuscript: Tarantino, Curigliano, Mittendorf, Tolaney.

Critical revision of the manuscript for important intellectual content: All authors.

Administrative, technical, or material support: Tarantino, Curigliano, Tolaney.

Supervision: Tarantino, Curigliano, Parsons, Krop, Tolaney.

Conflict of Interest Disclosures: Dr Tarantino has served as an adviser/consultant to AstraZeneca and is supported by an American-Italian Cancer Foundation Post-Doctoral Research Fellowship. Dr Curigliano received honoraria for speaker, consultancy, or advisory roles from Roche, Pfizer, Novartis, Seattle Genetics, Lilly, Ellipses Pharma, Foundation Medicine, Daiichi Sankyo, and Samsung. Dr Parsons is a paid consultant for Foundation Medicine. Dr Lin reports research support (to institution) from Genentech, Merck, Pfizer, and Seattle Genetics; consultant/advisory board: Puma, Seattle Genetics, Daiichi Sankyo, AstraZeneca, Denali Therapeutics, California Institute for Regenerative Medicine, and Prelude Therapeutics. Dr Krop reports research support (to institution) from Genentech/Roche and Pfizer, has received fees from Novartis and Merck for Data Monitoring Board participation, received honoraria from Celltrion, and has received consulting fees from Bristol Myers Squibb, Daiichi/Sankyo, Macrogenics, Context Therapeutics, Taiho Oncology, Genentech/Roche, Seattle Genetics, and AstraZeneca. Dr Mittendorf has received research support from GlaxoSmithKline; honoraria from Physician Education Resource; compensation for serving on advisory boards for AstraZeneca, Exact Sciences, Merck, Peregrine Pharmaceuticals, Roche/Genentech, Sellas Lifesciences, and TapImmune; institutional support from AstraZeneca, EMD Serono, Galena Biopharma, and Roche/Genentech; and has served as an uncompensated steering committee member for Bristol Myers Squibb, Lilly and Roche/Genentech. Dr Waks receives institutional research funding from Genentech/Roche. Dr Winer is a scientific advisory board member for Leap, and reports consultancy fees from Garrick Therapeutics, G1 Therapeutics, Roche Genentech, Genomic Health, GlaxoSmithKline, Jounce, Lilly, Novartis, Seattle Genetics, and Syros, outside the submitted work. Dr Tolaney receives institutional research funding from AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics/Gilead, Exelixis, Bristol Myers Squibb, Eisai, Nanostring, Cyclacel, Odonate, and Seattle Genetics; has served as an adviser/consultant to AstraZeneca, Eli Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics/Gilead, Bristol Myers Squibb, Eisai, Nanostring, Puma, Sanofi, Puma, Silverback Therapeutics, G1 Therapeutics, Athenex, OncoPep, Kyowa Kirin Pharmaceuticals, Daiichi-Sankyo, Ellipsis, Infinity, 4D Pharma, Samsung Bioepsis, Inc, Chugai Pharmaceuticals, BeyondSpring Pharmaceuticals, OncXerna, OncoSec Medical Incorporated, Certara, Mersana Therapeutics, CytomX, Seattle Genetics.

Additional Contributions: We thank Kate Bifolck, BA, for her editorial and submission assistance (full-time employee of Dana-Farber Cancer Institute).

References

Harbeck N , Penault-Llorca F , Cortes J , et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66. doi:10.1038/s41572-019-0111-2 PubMed Google Scholar Crossref

DeVita VT Jr , Chu E . A history of cancer chemotherapy. Cancer Res. 2008;68(21):8643-8653. doi:10.1158/0008-5472.CAN-07-6611 PubMed Google Scholar Crossref

Stadtmauer EA , O’Neill A , Goldstein LJ , et al; Philadelphia Bone Marrow Transplant Group. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med. 2000;342(15):1069-1076. doi:10.1056/NEJM200004133421501 PubMed Google Scholar Crossref

Cardoso F , Paluch-Shimon S , Senkus E , et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623-1649. doi:10.1016/j.annonc.2020.09.010 PubMed Google Scholar Crossref

Swain SM , Miles D , Kim S-B , et al; CLEOPATRA study group. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519-530. doi:10.1016/S1470-2045(19)30863-0 PubMed Google Scholar Crossref

Slamon DJ , Leyland-Jones B , Shak S , et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792. doi:10.1056/NEJM200103153441101 PubMed Google Scholar Crossref

Miles D , Ciruelos E , Schneeweiss A , et al; PERUSE investigators. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann Oncol. 2021;32(10):1245-1255. doi:10.1016/j.annonc.2021.06.024 PubMed Google Scholar Crossref

Battisti NML , Tong D , Ring A , Smith I . Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: the Royal Marsden experience. Breast Cancer Res Treat. 2019;178(2):401-408. doi:10.1007/s10549-019-05406-6 PubMed Google Scholar Crossref

Wong Y , Raghavendra AS , Hatzis C , et al. Long-term survival of de novo stage IV human epidermal growth receptor 2 (HER2) positive breast cancers treated with HER2-targeted therapy. Oncologist. 2019;24(3):313-318. doi:10.1634/theoncologist.2018-0213 PubMed Google Scholar Crossref

10.

Yeo B , Kotsori K , Mohammed K , Walsh G , Smith IE . Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab. Breast. 2015;24(6):751-757. doi:10.1016/j.breast.2015.09.008 PubMed Google Scholar Crossref

11.

Tripathy D , Brufsky A , Cobleigh M , et al. De novo versus recurrent HER2-positive metastatic breast cancer: patient characteristics, treatment, and survival from the SystHERs registry. Oncologist. 2020;25(2):e214-e222. doi:10.1634/theoncologist.2019-0446 PubMed Google Scholar Crossref

12.

Perou CM , Sørlie T , Eisen MB , et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752. doi:10.1038/35021093 PubMed Google Scholar Crossref

13.

Prat A , Carey LA , Adamo B , et al. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J Natl Cancer Inst. 2014;106(8):dju152. doi:10.1093/jnci/dju152 PubMed Google Scholar Crossref

14.

Harano K , Lei X , Gonzalez-Angulo AM , et al. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2016;159(2):367-374. doi:10.1007/s10549-016-3933-6 PubMed Google Scholar Crossref

15.

den Brok WD , Speers CH , Gondara L , Baxter E , Tyldesley SK , Lohrisch CA . Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. Breast Cancer Res Treat. 2017;161(3):549-556. doi:10.1007/s10549-016-4080-9 PubMed Google Scholar Crossref

16.

Malmgren JA , Mayer M , Atwood MK , Kaplan HG . Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010. Breast Cancer Res Treat. 2018;167(2):579-590. doi:10.1007/s10549-017-4529-5 PubMed Google Scholar Crossref

17.

Yardley DA , Tripathy D , Brufsky AM , et al. Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer. 2014;110(11):2756-2764. doi:10.1038/bjc.2014.174 PubMed Google Scholar Crossref

18.

Hopkins AM , Rowland A , McKinnon RA , Sorich MJ . Predictors of long-term disease control and survival for HER2-positive advanced breast cancer patients treated with pertuzumab, trastuzumab, and docetaxel. Front Oncol. 2019;9:789. doi:10.3389/fonc.2019.00789 PubMed Google Scholar Crossref

19.

Yates LR , Gerstung M , Knappskog S , et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med. 2015;21(7):751-759. doi:10.1038/nm.3886 PubMed Google Scholar Crossref

20.

Witzel I , Müller V , Abenhardt W , et al. Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer—results from the HER-OS patient registry. BMC Cancer. 2014;14(1):806. doi:10.1186/1471-2407-14-806 PubMed Google Scholar Crossref

21.

Baselga J , Lewis Phillips GD , Verma S , et al. Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. Clin Cancer Res. 2016;22(15):3755-3763. doi:10.1158/1078-0432.CCR-15-2499 PubMed Google Scholar Crossref

22.

Kim S-B , Wildiers H , Krop IE , et al. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician’s choice in previously treated HER2-positive advanced breast cancer. Int J Cancer. 2016;139(10):2336-2342. doi:10.1002/ijc.30276 PubMed Google Scholar Crossref

23.

Burris HA III , Rugo HS , Vukelja SJ , et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29(4):398-405. doi:10.1200/JCO.2010.29.5865 PubMed Google Scholar Crossref

24.

Esteva FJ , Guo H , Zhang S , et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol. 2010;177(4):1647-1656. doi:10.2353/ajpath.2010.090885 PubMed Google Scholar Crossref

25.

Luen SJ , Salgado R , Fox S , et al. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol. 2017;18(1):52-62. doi:10.1016/S1470-2045(16)30631-3 PubMed Google Scholar Crossref

26.

Tarantino P , Trapani D , Curigliano G . Mastering the use of novel anti-HER2 treatment options. JCO Oncol Pract. 2021;17(10):605-606. doi:10.1200/OP.21.00216 PubMed Google Scholar Crossref

27.

Tarantino P , Prat A , Cortes J , Cardoso F , Curigliano G . Third-line treatment of HER2-positive advanced breast cancer: from no standard to a Pandora’s box. Biochim Biophys Acta Rev Cancer. 2021;1875(1):188487. doi:10.1016/j.bbcan.2020.188487 PubMed Google Scholar Crossref

28.

Modi S , Saura C , Yamashita T , et al; DESTINY-Breast01 Investigators. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610-621. doi:10.1056/NEJMoa1914510 PubMed Google Scholar Crossref

29.

Cortes J , Kim S-B , Chung W-P , et al. LBA1—Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study. Ann Oncol. 2021;32(suppl_5):S1283-S1346.Google Scholar

30.

Murthy RK , Loi S , Okines A , et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597-609. doi:10.1056/NEJMoa1914609 PubMed Google Scholar Crossref

31.

Lin NU , Borges V , Anders C , et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020:JCO.20.00775. doi:10.1200/JCO.20.00775 Google Scholar Crossref

32.

Stemmler H-J , Schmitt M , Willems A , Bernhard H , Harbeck N , Heinemann V . Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs. 2007;18(1):23-28. doi:10.1097/01.cad.0000236313.50833.ee PubMed Google Scholar Crossref

33.

Swain SM , Baselga J , Miles D , et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol. 2014;25(6):1116-1121. doi:10.1093/annonc/mdu133 PubMed Google Scholar Crossref

34.

Pestalozzi BC , Holmes E , de Azambuja E , et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol. 2013;14(3):244-248. doi:10.1016/S1470-2045(13)70017-2 PubMed Google Scholar Crossref

35.

von Minckwitz G , Huang C-S , Mano MS , et al; KATHERINE Investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617-628. doi:10.1056/NEJMoa1814017 PubMed Google Scholar Crossref

36.

Rugo HS , Im SA , Cardoso F , et al; SOPHIA Study Group. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021;7(4):573-584. doi:10.1001/jamaoncol.2020.7932 PubMed Google Scholar Crossref

37.

Tarantino P , Morganti S , Curigliano G. Targeting HER2 in breast cancer: new drugs and paradigms on the horizon. Explor Target Anti-tumor Ther. 2021;2(2):139-155. doi:10.37349/etat.2021.00037 Google Scholar Crossref

38.

Salgado R , Denkert C , Campbell C , et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO Trial. JAMA Oncol. 2015;1(4):448-454. doi:10.1001/jamaoncol.2015.0830 PubMed Google Scholar Crossref

39.

Nuciforo P , Prat A , Llombart A , et al Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial. Ann Oncol. 2017;28:v46. doi:10.1093/annonc/mdx362.006 Google Scholar Crossref

40.

Hiam-Galvez KJ , Allen BM , Spitzer MH . Systemic immunity in cancer. Nat Rev Cancer. 2021;21(6):345-359. doi:10.1038/s41568-021-00347-z PubMed Google Scholar Crossref

41.

Michielin O , Atkins MB , Koon HB , Dummer R , Ascierto PA . Evolving impact of long-term survival results on metastatic melanoma treatment. J Immunother Cancer. 2020;8(2):e000948. doi:10.1136/jitc-2020-000948 PubMed Google Scholar Crossref

42.

Chapman PB , Einhorn LH , Meyers ML , et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17(9):2745-2751. doi:10.1200/JCO.1999.17.9.2745 PubMed Google Scholar Crossref

43.

Larkin J , Chiarion-Sileni V , Gonzalez R , et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535-1546. doi:10.1056/NEJMoa1910836 PubMed Google Scholar Crossref

44.

Wolchok JD , Chiarion-Sileni V , Gonzalez R , et al. CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma. J Clin Oncol. 2021;39(suppl_15):9506-9506. doi:10.1200/JCO.2021.39.15_suppl.9506 Google Scholar Crossref

45.

Reck M , Rodríguez-Abreu D , Robinson AG , et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score ≥ 50%. J Clin Oncol. 2021;39(21):2339-2349. doi:10.1200/jco.21.00174 Google Scholar Crossref

46.

Albiges L , Tannir NM , Burotto M , et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020;5(6):e001079. doi:10.1136/esmoopen-2020-001079 PubMed Google Scholar Crossref

47.

Nghiem P , Bhatia S , Brohl AS , et al. Avelumab in patients with previously treated Merkel cell carcinoma (JAVELIN Merkel 200): Updated overall survival data after more than five years of follow up. J Clin Oncol. 2021;39(suppl_15):9517-9517. doi:10.1200/JCO.2021.39.15_suppl.9517 Google Scholar Crossref

48.

Clynes RA , Towers TL , Presta LG , Ravetch JV . Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6(4):443-446. doi:10.1038/74704 PubMed Google Scholar Crossref

49.

Park S , Jiang Z , Mortenson ED , et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell. 2010;18(2):160-170. doi:10.1016/j.ccr.2010.06.014 PubMed Google Scholar Crossref

50.

Stagg J , Loi S , Divisekera U , et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A. 2011;108(17):7142-7147. doi:10.1073/pnas.1016569108 PubMed Google Scholar Crossref

51.

Emens LA , Esteva FJ , Beresford M , et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020;21(10):1283-1295. doi:10.1016/S1470-2045(20)30465-4 PubMed Google Scholar Crossref

52.

Loi S , Giobbie-Hurder A , Gombos A , et al; International Breast Cancer Study Group and the Breast International Group. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. Lancet Oncol. 2019;20(3):371-382. doi:10.1016/S1470-2045(18)30812-X PubMed Google Scholar Crossref

53.

Huober J , Barrios CH , Niikura N , et al VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk, HER2-positive early breast cancer (EBC). Ann Oncol. 2021;32(8):1061-1062. doi:10.1016/j.annonc.2021.05.800 Google Scholar Crossref

54.

Criscitiello C , Giuliano M , Curigliano G , et al. Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do? Eur J Surg Oncol. 2015;41(10):1288-1292. doi:10.1016/j.ejso.2015.07.013 PubMed Google Scholar Crossref

55.

Cardoso M-J , Mokbel K . Locoregional therapy in de novo metastatic breast cancer. The unanswered question. Breast. 2021;58:170-172. doi:10.1016/j.breast.2021.05.002 PubMed Google Scholar Crossref

56.

Khan SA , Zhao F , Solin LJ , et al. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108). J Clin Oncol. 2020;38(suppl_18):LBA2-LBA2. doi:10.1200/JCO.2020.38.18_suppl.LBA2 Google Scholar Crossref

57.

Lo SS , Fakiris AJ , Chang EL , et al. Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol. 2010;7(1):44-54. doi:10.1038/nrclinonc.2009.188 PubMed Google Scholar Crossref

58.

Ignatiadis M , Sledge GW , Jeffrey SS . Liquid biopsy enters the clinic—implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18(5):297-312. doi:10.1038/s41571-020-00457-x PubMed Google Scholar Crossref

59.

Janni WJ , Yab TC , Hayes DF , et al. Abstract GS4-08: Clinical utility of repeated circulating tumor cell (CTC) enumeration as early treatment monitoring tool in metastatic breast cancer (MBC)—a global pooled analysis with individual patient data. In: General Session Abstracts. American Association for Cancer Research. 2021:GS4-08-GS4-08. doi:10.1158/1538-7445.SABCS20-GS4-08

60.

Guan X , Liu B , Niu Y , et al. Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer. Breast. 2020;49:261-266. doi:10.1016/j.breast.2019.12.010 PubMed Google Scholar Crossref

61.

Ma F , Zhu W , Guan Y , et al. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy. Oncotarget. 2016;7(40):66020-66031. doi:10.18632/oncotarget.11791 PubMed Google Scholar Crossref

62.

Ngai LL , Kelder A , Janssen JJWM , Ossenkoppele GJ , Cloos J . MRD tailored therapy in AML: what we have learned so far. Front Oncol. 2021;10:603636. doi:10.3389/fonc.2020.603636 PubMed Google Scholar Crossref

63.

Richter J , Lübking A , Söderlund S , et al. Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI. Leukemia. 2021;35(8):2416-2418. doi:10.1038/s41375-021-01173-w PubMed Google Scholar Crossref

AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
1.00 credit toward the CME [and Self-Assessment requirements] of the American Board of Surgery’s Continuous Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.

Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast CancerA Review

Aiming for the Cure in ERBB2-Positive Metastatic Breast Cancer—Should We Go “All In”?

See More About

AMA CME Accreditation Information

Want full access to the AMA Ed Hub?

AMA Membership provides:

Sign in to access

Want full access to the AMA Ed Hub?

Sign in to customize your interests

With a personal account, you can:

Name Your Search

Sign in to save your search

With a personal account, you can:

Lookup An Activity

My Saved Searches

My Saved Courses

Purchase access